Growth Metrics

Thermo Fisher Scientific (TMO) Equity Income (2021 - 2026)

Thermo Fisher Scientific filings provide 6 years of Equity Income readings, the most recent being -$8.0 million for Q1 2026.

  • On a quarterly basis, Equity Income rose 42.86% to -$8.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$36.0 million, a 54.43% increase, with the full-year FY2025 number at -$41.0 million, up 2.38% from a year prior.
  • Equity Income hit -$8.0 million in Q1 2026 for Thermo Fisher Scientific, up from -$32.0 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $33.0 million in Q4 2024 to a low of -$84.0 million in Q2 2024.
  • Median Equity Income over the past 5 years was -$16.0 million (2023), compared with a mean of -$19.0 million.
  • Biggest five-year swings in Equity Income: tumbled 5000.0% in 2022 and later surged 3400.0% in 2024.
  • Thermo Fisher Scientific's Equity Income stood at -$30.0 million in 2022, then surged by 96.67% to -$1.0 million in 2023, then surged by 3400.0% to $33.0 million in 2024, then crashed by 196.97% to -$32.0 million in 2025, then soared by 75.0% to -$8.0 million in 2026.
  • The last three reported values for Equity Income were -$8.0 million (Q1 2026), -$32.0 million (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.